Corpus overview


Overview

MeSH Disease

Human Phenotype

Hypertension (6)

Fever (3)

Cough (3)

Myalgia (3)

Fatigue (3)


Transmission

Seroprevalence
    displaying 1 - 10 records in total 10
    records per page




    Clinical Determinants of the Severity of Coronavirus Disease MESHD 2019 (COVID-19): A Systematic Review and Meta-Analysis

    Authors: Yanling Wu; Hu Li; Shengjin Li

    doi:10.21203/rs.3.rs-56852/v1 Date: 2020-08-10 Source: ResearchSquare

    Background: SARS-CoV-2 is an emerging pathogen, and coronavirus disease MESHD 2019 (COVID-19) has been declared a global pandemic. We aim to summarize current evidence regarding the risk of death MESHD and the severity of COVID-19 as well as risk factors for severe COVID-19.Methods: The PubMed, Embase, and Web of Science databases as well as some Chinese databases were searched for clinical and epidemiological studies on COVID-19. We conducted a meta-analysis to examine COVID-19-related death MESHD and risk factors for the severity of COVID-19.Results: A total of 55 studies fulfilled the criteria for this review. The case fatality risk ranged from 0 to 61.5%, with a pooled estimate of 3.3%. The risks of ICU admission, acute respiratory distress syndrome MESHD respiratory distress HP syndrome ( ARDS MESHD)and severe COVID-19 were 24.9%, 20.9% and 26.6%, respectively. Factors related to the risk of severe COVID-19 were older age TRANS (MD=10.09, 95% CI:7.03, 13.16), male TRANS sex (OR=1.62, 95% CI:1.32, 1.99), hypertension HP hypertension MESHD (OR=2.34, 95% CI:1.47, 3.73), diabetes MESHD (OR=2.25, 95% CI:1.68, 3.03), chronic renal disease MESHD (OR=3.60, 95% CI:1.53, 8.46), heart disease MESHD (OR=2.76, 95% CI:1.78, 4.30), respiratory disease MESHD (OR=3.74, 95% CI:2.15, 6.49), cerebrovascular disease MESHD (OR=2.21, 95% CI:1.23, 3.98), higher D-dimer levels (SMD=0.62, 95% CI:0.28, 0.96), and higher IL-6 levels (SMD=2.21, 95% CI:0.11, 4.31). However, liver disease MESHD (OR=0.63, 95% CI: 0.36, 1.10) was found to be a nonsignificant predictor of the severity of COVID-19.Conclusions: The case fatality risk of COVID-19 and the risk of severe manifestations were not very high, and variances in the study designs and regions led to high heterogeneity among the studies. Male TRANS sex, older age TRANS, comorbidities such as hypertension HP hypertension MESHD, diabetes MESHD, cardiovascular disease MESHD, respiratory disease MESHD and cerebrovascular disease MESHD could increase the risk of developing a severe case of COVID-19. Laboratory parameters, such as D-dimer and IL-6 levels, could affect the prognosis of COVID-19.

    Complex Immuno-metabolic Profiling Reveals Activation of Cellular Immunity and Biliary Lesion MESHD in Patients with Severe COVID-19

    Authors: Adam Klocperk; Marketa Bloomfield; Zuzana Parackova; Irena Zentsova; Petra Vrabcova; Jan Balko; Grigorij Meseznikov; Luis Fernando Casas Mendez; Alzbeta Grandcourtova; Jan Sipek; Martin Tulach; Josef Zamecnik; Tomas Vymazal; Anna Sediva

    id:10.20944/preprints202007.0596.v1 Date: 2020-07-24 Source: Preprints.org

    The aim of this study was to assess the key laboratory features displayed by coronavirus disease MESHD 2019 (COVID-19) inpatients which associated with mild, moderate, severe and fatal course of the disease and, through longitudinal follow-up, to understand the dynamics of COVID-19 pathophysiology. All SARS-CoV-2 positive patients admitted to the University Hospital in Motol between March and June 2020 were included in this study. Severe course of COVID-19 was associated with elevation of proinflammatory markers, efflux of immature granulocytes into peripheral blood SERO, activation of CD8 T cells, which infiltrate lungs, and transient liver disease MESHD. In particular, the elevation of serum SERO gamma-glutamyl transferase (GGT) and histological signs of cholestasis HP cholestasis MESHD were highly specific for patients with severe disease. In contrast, patients with fatal course of COVID-19 failed to upregulate markers of inflammation MESHD, showed dyscoordination MESHD of immune response and progressed towards acute kidney failure MESHD. COVID-19 is a disease with multi-organ affinity characterized by activation of innate and cellular adaptive immunity. Biliary lesion MESHD with elevation of GGT and organ-infiltration of IL-6 producing cells are defining characteristic for patients with fulminant disease.

    Dynamic changes of liver function parameters in patients with coronavirus disease MESHD 2019: A multicenter, retrospective study

    Authors: Qing-Lei Zeng; Zu-Jiang Yu; Fanpu Ji; Guang-Ming Li; Guo-Fan Zhang; Jiang-Hai Xu; Wan-Bao Lin; Guo-Qiang Zhang; Guo-Tao Li; Guang-Lin Cui; Fu-Sheng Wang

    doi:10.21203/rs.3.rs-48131/v1 Date: 2020-07-23 Source: ResearchSquare

    Background: Liver injuries MESHD in patients with coronavirus disease MESHD 2019 (COVID-19) have been reported, however, the clinical role played by severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) is obscure.  Methods: In this multicenter, retrospective study, the parameters of liver function tests in COVID-19 inpatients were compared between various timepoints referred to SARS-CoV-2 shedding, and 3 to 7 days before first detection of viral shedding was regarded as reference baseline.Results: Totally, 70 COVID-19 inpatients were enrolled. Twenty-two (31.4%) cases had self-medications history after illness. At baseline, 10 (14.3%), 7 (10%), 9 (12.9%), 2 (2.9%), 15 (21.4%), and 4 (5.7%) patients already had abnormal rates of alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), alkaline phosphatase (ALP), albumin, and total bilirubin (TBIL), respectively. ALT and AST abnormal rates and levels did not show any significantly dynamic change during the full period of viral shedding (all P > 0.05). GGT abnormal rate (P = 0.008) and level (P = 0.033) significantly increased on day 10 of viral shedding. Meanwhile, no simultaneously significant increases of ALP abnormal rates and levels were observed. TBIL abnormal rates and levels significantly increased on day 1 and 5 of viral shedding (all P < 0.05). Albumin abnormal decrease rates increased and levels decreased consistently from baseline to SARS-CoV-2 clearance day (all P < 0.05). Thirteen (18.6%) patients had chronic liver diseases MESHD, two of them died. The ALT and AST abnormal rates and levels did not increase in patients with chronic liver diseases MESHD during SARS-CoV-2 shedding.Conclusions: The SARS-CoV-2 does not directly lead to elevations of ALT and AST, but may result in elevations of GGT and TBIL, the albumin decreased extraordinarily even SARS-CoV-2 shedding discontinued.

    Poor Outcomes in Patients with Cirrhosis HP Cirrhosis MESHD and COVID-19

    Authors: Shalimar; Anshuman Elhence; Manas Vaishnav; Ramesh Kumar; Piyush Pathak; Kapil Dev Soni; Richa Aggarwal; Manish Soneja; Pankaj Jorwal; Arvind Kumar; Puneet Khanna; Akhil Kant Singh; Ashutosh Biswas; Neeraj Nischal; Lalit Dhar; Aashish Choudhary; Krithika Rangarajan; Anant Mohan; Pragyan Acharya; Baibaswata Nayak; Deepak Gunjan; Anoop Saraya; Soumya Mahapatra; Govind Makharia; Anjan Trikha; Pramod Garg

    doi:10.21203/rs.3.rs-40220/v1 Date: 2020-07-06 Source: ResearchSquare

    Background and AimThere is a paucity of data on the clinical presentations and outcomes of Coronavirus disease MESHD 2019(COVID-19) in patients with underlying liver disease MESHD. We aimed to summarize the presentations and outcomes of COVID-19 positive patients and compare with historical controls.MethodsPatients with known chronic liver disease MESHD who presented with superimposed COVID- 19(n=28) between 22nd April and 22nd June 2020 were studied. Seventy-eight cirrhotic patients from historical controls were taken as comparison group.ResultsA total of 28 COVID patients- two without cirrhosis HP cirrhosis MESHD, one with compensated cirrhosis HP cirrhosis MESHD, sixteen with acute decompensation (AD), and nine with acute-on-chronic liver failure MESHD( ACLF MESHD) were included. The etiology of cirrhosis HP cirrhosis MESHD was alcohol(n=9), non-alcoholic fatty liver disease MESHD(n=2), viral(n=5), autoimmune hepatitis MESHD hepatitis HP(n=4), and cryptogenic cirrhosis HP(n=6). The clinical presentations included complications of cirrhosis HP cirrhosis MESHD in 12(46.2%), respiratory symptoms in 3(11.5%) and combined complications of cirrhosis HP cirrhosis MESHD and respiratory symptoms in 11(42.3%) patients. The median hospital stay was 8(7-12) days. The mortality rate in COVID-19 patients was 42.3%(11/26), as compared to 23.1%(18/78) in the historical controls(p=0.077). All COVID-19 patients with ACLF(9/9) died compared to 53.3%(16/30) in ACLF of historical controls(p=0.015). Mortality rate was higher in COVID patients with compensated cirrhosis HP cirrhosis MESHD and AD MESHD as compared to historical controls 2/17(11.8%) vs 2/48(4.2%), though not statistically significant (p=0.278). Requirement of mechanical ventilation independently predicted mortality (hazard ratio, 13.68). Both non-cirrhotic patients presented with respiratory symptoms MESHD and recovered uneventfully.ConclusionCOVID-19 is associated with poor outcomes in patients with cirrhosis HP cirrhosis MESHD, with worst survival rates in ACLF. Mechanical ventilation is associated with a poor outcome.

    The influence of comorbidity on the severity of COVID-19 disease: systematic review and analysis

    Authors: Nazar Zaki; Elfadil Abdalla Mohamed; Sahar Ibrahim; Gulfaraz Khan

    doi:10.21203/rs.3.rs-37127/v1 Date: 2020-06-20 Source: ResearchSquare

    Background: A novel form of coronavirus disease MESHD (SARS-CoV-2) has spread rapidly across the world. This disease, originating in Wuhan, China, has become a global pandemic. What risk factors influence the severity of the disease is of considerable importance.Aim: This research is intended to offer a systematic review/meta-analysis for assessing how common clinical conditions and comorbidities correlate with COVID-19.Methodology: Two independent researchers undertook searches using Europe PMC, Google Scholar, and PubMed. In addition, a search engine was created for screening another 59,000 articles in COVID-19 Open Research Dataset (CORD-19). Screening was undertaken for any article related to comorbidity and their influence on the progress of the disease. Random-effects modeling was used to pool 95% confidence intervals (CIs) and odds ratios (ORs). The significance of all comorbidities and clinical conditions in relation to the severity of the disease were evaluated by employing feature extraction methods and machine-learning. Publication bias was assessed by employing funnel plots, and heterogeneity was tested in relation to I2.Results: The meta-analysis incorporated 12 studies covering 4101 confirmed COVID-19 patients from Chinese hospitals. The findings demonstrate that the most common comorbidities with the disease were hypertension HP hypertension MESHD (22.07%, OR 2.43 [95% CI: 1.71-3.45], p <0.0001), diabetes MESHD (11.34%, OR 2.27, [95% CI: 1.46-3.53], p = 0.0003), cardiovascular disease MESHD (10.76%, OR 2.89 [95% CI: 1.90-4.40], p <0.0001), and COPD (2.53%, OR 3.24 [95% CI: 1.99-4.45], p< 0.0006). No significant associations were found for disease severity with the comorbidities of kidney disease MESHD, liver disease MESHD, or cancer MESHD.The most frequently exhibited clinical symptoms were fever HP fever MESHD (74.52%, OR 1.37, 95% CI: 1.01-1.86, p = 0.04), cough HP (62.15%, OR 1.25, 95% CI: 0.97-1.60, p = 0.0823), myalgia HP myalgia MESHD/ fatigue HP fatigue MESHD (38.77%, OR 1.31, 95% CI: 1.11-1.55, p = 0.0018), dyspnea HP dyspnea MESHD (33.9%, OR 3.61, 95% CI: 2.57-5.06, p = <0.0001), and respiratory failure HP respiratory failure MESHD/ARDS (20.6%, OR 11.46, 95% CI: 3.24-40.56, p = 0.0002). Meta-analysis also revealed that neither the duration of the incubation period TRANS nor current smoking status associated with disease severity.Conclusion: Existing comorbidities, including COPD, cardiovascular disease MESHD, coronary heart disease MESHD, diabetes MESHD, and hypertension HP hypertension MESHD represent a risk of increasing the severity of the disease in COVID-19 patients.

    The influence of comorbidity on the severity of COVID-19 disease: systematic review and analysis

    Authors: Nazar Zaki; Elfadil Abdalla Mohamed; Sahar Ibrahim; Gulfaraz Khan

    doi:10.1101/2020.06.18.20134478 Date: 2020-06-20 Source: medRxiv

    A novel form of coronavirus disease MESHD (SARS-CoV-2) has spread rapidly across the world. This disease, originating in Wuhan, China, has become a global pandemic. What risk factors influence the severity of the disease is of considerable importance. This research is intended to offer a systematic review/meta-analysis for assessing how common clinical conditions and comorbidities correlate with COVID-19. The meta-analysis incorporated seven studies covering 4101 COVID-19 patients from Chinese hospitals who had their diagnosis confirmed through laboratory testing. The findings demonstrate that the most common comorbidities with the disease were COPD MESHD (2.53%, OR 3.24 [95% CI: 1.99-4.45], p< 0.0006), cardiovascular disease MESHD (10.76%, OR 2.89 [95% CI: 1.90-4.40], p <0.0001), coronary heart disease MESHD (5.52%, OR 2.97 [95% CI: 1.99-4.45], p <0.0001), diabetes MESHD (11.34%, OR 2.27, [95% CI: 1.46-3.53], p = 0.0003), and hypertension HP hypertension MESHD (22.07%, OR 2.43 [95% CI: 1.71-3.45], p <0.0001). No significant associations were found for disease severity with the comorbidities of kidney disease MESHD, liver disease MESHD, or cancer MESHD. The most frequently exhibited clinical symptoms were fever HP fever MESHD (74.52%, OR 1.37, 95% CI: 1.01-1.86, p = 0.04), cough HP (62.15%, OR 1.25, 95% CI: 0.97-1.60, p = 0.0823), myalgia HP myalgia MESHD/ fatigue HP fatigue MESHD (38.77%, OR 1.31, 95% CI: 1.11-1.55, p = 0.0018), dyspnea HP dyspnea MESHD (33.9%, OR 3.61, 95% CI: 2.57-5.06, p = <0.0001), respiratory failure HP respiratory failure MESHD/ARDS (20.6%, OR 11.46, 95% CI: 3.24-40.56, p = 0.0002), diarrhea HP diarrhea MESHD (11.21%) and chest tightness HP chest tightness MESHD/ pain HP (16.82%, OR 2.17, 95% CI: 1.40-3.36, p = 0.0006). Meta-analysis also revealed that neither the duration of the incubation period TRANS nor current smoking status associated with disease severity.

    The influence of comorbidity on the severity of COVID-19 disease: A systematic review and analysis

    Authors: Nazar Zaki; Elfadil Abdalla Mohamed; Sahar Ibrahim; Gulfaraz Khan

    doi:10.21203/rs.3.rs-37127/v2 Date: 2020-06-20 Source: ResearchSquare

    Background: A novel form of coronavirus disease MESHD (SARS-CoV-2) has spread rapidly across the world. What risk factors influence the severity of the disease is of considerable importance.Aim: This research offers a systematic review and meta-analysis of the correlation between common clinical conditions and comorbidities and the severity of COVID-19.Methodology: Two independent researchers searched Europe PMC, Google Scholar, and PubMed databases for articles related to influence comorbidities have on the progress of the disease. A search engine was also created to screen a further 59,000 articles in COVID-19 Open Research Dataset (CORD-19). Random-effects modeling was used to pool 95% confidence intervals (CIs) and odds ratios (ORs). The significance of all comorbidities and clinical conditions to the severity of the disease was evaluated by employing machine-learning techniques. Publication bias was assessed by using funnel-plots and Egger’s test. Heterogeneity was tested using I2.Results: The meta-analysis incorporated 12 studies spanning 4,101 confirmed COVID-19 patients who were admitted to Chinese hospitals. The prevalence SERO of the most commonly associated co-morbidities and their corresponding odds ratio for disease severity were as follows: coronary heart disease MESHD (OR 2.97 [CI: 1.99-4.45], p < 0.0001), cancer MESHD (OR 2.65 [CI: 1.12-6.29], p < 0.03), cardiovascular disease MESHD (OR 2.89 [CI: 1.90-4.40], p < 0.0001), COPD MESHD (OR 3.24 [CI: 1.66-6.32], p = 0.0), and kidney disease MESHD (OR 2.2.4 [CI: 1.01-4.99], p = 0.05) with low or moderate level of heterogeneity. The most frequently exhibited clinical symptoms were fever HP fever MESHD (OR 1.37 [CI: 1.01-1.86], p = 0.04), myalgia HP myalgia MESHD/ fatigue HP fatigue MESHD (OR 1.31 [CI: 1.11-1.55], p = 0.0018), and dyspnea HP dyspnea MESHD (OR 3.61, [CI: 2.57-5.06], p = <0.0001). No significant associations between disease severity and liver disease MESHD, smoking habits, and other clinical conditions, such as a cough HP, respiratory/ARDS, diarrhea HP diarrhea MESHD or chest tightness HP chest tightness MESHD/ pain HP pain MESHD were found. The meta-analysis also revealed that the incubation period TRANS was positively associated with disease severity. Conclusion: Existing comorbidities, including COPD, cardiovascular disease MESHD, and coronary heart disease MESHD, increase the severity of COVID-19. Some studies found a statistically significant association between comorbidities such as diabetes MESHD and hypertension HP hypertension MESHD and disease severity. However, these studies may be biased due to substantial heterogeneity. 

    Clinical retrospective analysis of 70 discharged patients with the Coronavirus disease MESHD 2019 (COVID-19) in Hangzhou, Zhejiang Province

    Authors: Zhongbao Zuo; Jing Wu; Miaochan Wang; Yujiao Jin; Wenyan Yu; Haiying Niu; Yangjun Chen; Pengbo Liu; Deyu Zeng; Dongming Sui; Zhaobin Cai; Aifang Xu

    doi:10.21203/rs.3.rs-27333/v1 Date: 2020-05-07 Source: ResearchSquare

    Background Since the Coronavirus Disease MESHD 2019 (COVID-19) was first identified in Wuhan, China, caused by the Severe Acute Respiratory Syndrome Coronavirus 2 MESHD (SARS-CoV-2) pathogen, the disease has been found in many countries. Considering the lack of effective drugs and rapid spread of COVID-19, we did a clinical detailed retrospective analysis of 70 discharged patients which can help us to better determine the clinical features of the disease.Method We collected demographic, epidemiological, clinical, laboratory, and chest computed tomographic (CT) data from patients’ hospital records, the time period were from hospitalization day1 to day7 and hospitalization last day. The retrospective study totally included 70 COVID-19 patients.Results The median age TRANS was 43 (IQR: 34-56) years. 41 (58.6%) patients were female TRANS, and there were 33 (47.1%) patients who were hospitalized more than 14 days. 18 (25.7%) patients were residents of Wuhan or recently travelled TRANS to Wuhan, 38 (54.3%) patients were having a close contact TRANS with the COVID-19 patients. The most common pre-existing diseases were liver disease MESHD (15.7%), hypertension HP hypertension MESHD (12.9%), renal disease MESHD (8.6), lung disease MESHD (5.7%). The time from illness onset to hospitalization was 4 (IQR: 2-7) days. The most common treatment regimen was Lopinavir/ritonavir (LPV) + Interferon alpha inhalation (IAI) + Arbidol. Compared with hospitalization day1, White blood SERO cell count, C-reacting protein, Potassium, Aspartate aminotransferase, Lactate dehydrogenase, and Lactic acid were significantly different than hospitalization day-last. The median number of times a patients receiving chest computed tomography (CT) from day1 to day7 was 3 (IQR: 3-4). The typical chest computed tomographic images were patchy shadows and ground glass opacity.Conclusion Currently, there are no specific antiviral therapies for COVID-19. 70 COVID-19 patients in our study responded positively to treatment during the two-week period. For those discharged patients with abnormal results, more attention is needed in the future studies to control the transmission TRANS

    Clinical retrospective analysis of 70 discharged patients with the Coronavirus disease MESHD 2019 (COVID-19) in Hangzhou, Zhejiang Province

    Authors: Zhongbao Zuo; Jing Wu; Miaochan Wang; Yujiao Jin; Wenyan Yu; Haiying Niu; Yangjun Chen; Pengbo Liu; Deyu Zeng; Dongming Sui; Zhaobin Cai; Aifang Xu

    doi:10.21203/rs.3.rs-19398/v1 Date: 2020-03-25 Source: ResearchSquare

    Background Since the Coronavirus Disease MESHD 2019 (COVID-19) was first identified in Wuhan, China, caused by the Severe Acute Respiratory Syndrome Coronavirus 2 MESHD (SARS-CoV-2) pathogen, the disease has been found in many countries. Considering the lack of effective drugs and rapid spread of COVID-19, we did a clinical detailed retrospective analysis of 70 discharged patients which can help us to better determine the clinical features of the disease. Method We collected demographic, epidemiological, clinical, laboratory, and chest computed tomographic (CT) data from patients’ hospital records, the time period were from hospitalization day1 to day7 and hospitalization last day. The retrospective study totally included 70 COVID-19 patients. Results The median age TRANS was 43 (IQR: 34-56) years. 41 (58.6%) patients were female TRANS, and there were 33 (47.1%) patients who were hospitalized more than 14 days. 18 (25.7%) patients were residents of Wuhan or recently travelled TRANS to Wuhan, 38 (54.3%) patients were having a close contact TRANS with the COVID-19 patients. The most common pre-existing diseases were liver disease MESHD (15.7%), hypertension HP hypertension MESHD (12.9%), renal disease MESHD (8.6), lung disease MESHD (5.7%). The time from illness onset to hospitalization was 4 (IQR: 2-7) days. The most common treatment regimen was Lopinavir/ritonavir (LPV) + Interferon alpha inhalation (IAI) + Arbidol. Compared with hospitalization day1, White blood SERO cell count, C-reacting protein, Potassium, Aspartate aminotransferase, Lactate dehydrogenase, and Lactic acid were significantly different than hospitalization day-last. The median number of times a patients receiving chest computed tomography (CT) from day1 to day7 was 3 (IQR: 3-4). The typical chest computed tomographic images were patchy shadows and ground glass opacity. Conclusion Currently, there are no specific antiviral therapies for COVID-19. 70 COVID-19 patients in our study responded positively to treatment during the two-week period. For those discharged patients with abnormal results, more attention is needed in the future studies to control the transmission TRANS.

    scRNA-seq reveals ACE2 and TMPRSS2 expression in TROP2+ Liver Progenitor Cells: Implications in COVID-19 associated Liver Dysfunction

    Authors: Justine Jia Wen Seow; Rhea Pai; Archita Mishra; Edwin Shepherdson; Tony Kiat Hon Lim; Brian K P Goh; Jerry KY Chan; Pierce KH Chow; Florent Ginhoux; Ramanuj DasGupta; Ankur Sharma

    doi:10.1101/2020.03.23.002832 Date: 2020-03-25 Source: bioRxiv

    The recent pandemic of coronavirus disease MESHD 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2). COVID-19 was first reported in China (December 2019) and now prevalent in [~]170 countries across the globe. Entry of SARS-CoV-2 into mammalian cells require the binding of viral Spike (S) proteins to the ACE2 (angiotensin converting enzyme 2) receptor. Once entered the S protein is primed by a specialised serine protease, TMPRSS2 (Transmembrane Serine Protease 2) in the host cell. Importantly, beside respiratory symptoms, consistent with other common respiratory virus infection MESHD when patients become viraemic, a significant number of COVID-19 patients also develop liver comorbidities. We explored if specific target cell-type in the mammalian liver, could be implicated in disease pathophysiology other than the general deleterious response to cytokine storms. Here we employed single-cell RNA-seq (scRNA-seq) to survey the human liver and identified potentially implicated liver cell-type for viral ingress. We report the co-expression of ACE2 and TMPRSS2 in a TROP2+ liver progenitor population. Importantly, we fail to detect the expression of ACE2 in hepatocyte or any other liver (immune and stromal) cell types. These results indicated that in COVID-19 associated liver dysfunction MESHD and cell death, viral infection of TROP2+ progenitors in liver may significantly impaired liver regeneration and could lead to pathology. Highlights- EPCAM+ Liver progenitors co-express ACE2 and TMPRSS2 - ACE2 and TMPRSS2 expression is highest in TROP2high progenitors - ACE2 and TMPRSS2 cells express cholangiocyte biased fate markers - ACE2 and TMPRSS2 positive cells are absent in human fetal liver

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.